Fundraising Fox

Antag Therapeutics

Copenhagen, DK · Founded 2017 · 23 employees on LinkedIn · 10 known investors

Find your way into Antag Therapeutics

212 people in our graph share verified history with the Antag Therapeutics team — schools, employers, funds. One of them is your warm intro.

Jesper Gromadaunlockedknows Mette Rosenkilde · together at Københavns Universitet - University of Copenhagen (overlapped)
×11knows the team · via Københavns Universitet - University of Copenhagen

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.

BiotechHealthtech

Founders & leadership

Antag Therapeutics was founded in 2017 by Jens Juul Holst and Mette Rosenkilde.

JJ
Jens Juul HolstFounder
MRMette Rosenkilde
Mette RosenkildeinFounderMette Rosenkilde is a pharmacologist and researcher at Copenhagen University focused on G protein-coupled receptor biology and metabolic diseases; she founded Antag Therapeutics based on years of collaborative research at the university to develop novel treatments for dietary-related metabolic disorders.

Investors · 10

Broadview VenturesBoston
Novo HoldingsCopenhagen · $1.1M – $54M
SR One Capital ManagementRedwood City
Versant Venturesreported · 3 sourcesSan Francisco · $250K – $5M

Also in the syndicate · 6

Dawn BiopharmaExport and Investment Fund of DenmarkExport and Investment Fund of Denmark (EIFO)Longview VenturesPictetSR One

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries ADec 2024 · 2 sources

    Versant Ventures (lead), Dawn Biopharma, Export and Investment Fund of Denmark, Export and Investment Fund of Denmark (EIFO), Longview Ventures, Novo Holdings, Pictet, SR One

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687 - BioSpacebiospace.com · Jul 2026Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors | FirstWord Pharmafirstwordpharma.com · Jun 2026Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officerglobenewswire.com · May 2026Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions - BioSpacebiospace.com · Apr 2026Novo Holdings-backed Antag raises $84M series A to send complementary obesity candidate to the clinicfiercebiotech.com · Dec 2024Antag Therapeutics Announces €80 Million Series A Financingprnewswire.com · Dec 2024

Frequently asked questions

What does Antag Therapeutics do?
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.
Who founded Antag Therapeutics?
Antag Therapeutics was founded by Jens Juul Holst, Mette Rosenkilde in 2017.
Who are Antag Therapeutics's investors?
Antag Therapeutics's investors include Broadview Ventures, Novo Holdings, SR One Capital Management, Versant Ventures.
Where is Antag Therapeutics headquartered?
Antag Therapeutics is headquartered in Copenhagen, DK.